2025
Comprehensive molecular and immune characterization of adrenergic stress-signaling receptor ADRB2 in triple negative breast cancer (TNBC).
Deshmukh S, Wu S, Xiu J, Hong C, Yao S, Sudmeier L, Kalinski P, Chalasani P, Repasky E, Ernstoff M, Leone J, Chumsri S, Graff S, Lustberg M, Sledge G, Kalinsky K, Gandhi S. Comprehensive molecular and immune characterization of adrenergic stress-signaling receptor ADRB2 in triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2025, 43: 1107-1107. DOI: 10.1200/jco.2025.43.16_suppl.1107.Peer-Reviewed Original ResearchTriple negative breast cancerBreast cancerOverall survivalTumor microenvironmentReal-world overall survivalADRB2 gene expressionNegative breast cancerImmune cell fractionsB2 adrenergic receptorPromote tumor growthMann-Whitney U testHighest survival benefitTriple negative breast cancer samplesKaplan-Meier estimatesSurvival benefitImmunological featuresGene expressionPreclinical modelsImmune characterizationTumor growthMann-WhitneyObservational studyU testADRB2RNA expressionCharacterization and lineage tracing of a mouse adipose depot reveal properties conserved with human supraclavicular brown adipose tissue
Li L, Feldman B. Characterization and lineage tracing of a mouse adipose depot reveal properties conserved with human supraclavicular brown adipose tissue. Stem Cell Reports 2025, 20: 102509. PMID: 40409261, PMCID: PMC12181967, DOI: 10.1016/j.stemcr.2025.102509.Peer-Reviewed Original ResearchConceptsInguinal white adipose tissueBrown adipose tissueSupraclavicular brown adipose tissuePreclinical modelsAdipose tissueActivation of beige adipocytesBeige adipose tissueAdipose tissue developmentWhite adipose tissueRobust preclinical modelsBeige fatDevelopmental originsMolecular markersSuccess of therapyTissue developmentThermogenic activityAdipose tissue depotsLineage tracingCell originLineagesAdipose depotsTherapeutic benefitMetabolic disordersTissue depotsMicePartial mitochondrial involvement in the antiproliferative and immunostimulatory effects of PT-112
Soler-Agesta R, Beltrán-Visiedo M, Sato A, Yamazaki T, Guilbaud E, Yim C, Congenie M, Ames T, Anel A, Galluzzi L. Partial mitochondrial involvement in the antiproliferative and immunostimulatory effects of PT-112. OncoImmunology 2025, 14: 2507245. PMID: 40386940, PMCID: PMC12091903, DOI: 10.1080/2162402x.2025.2507245.Peer-Reviewed Original ResearchConceptsImmunogenic cell deathTS/A cellsPD-L1Immune checkpoint inhibitorsExposure of calreticulinLigand PD-L1Type I IFN secretionSecrete type I IFNsRelease of HMGB1MHC class IMHC class I moleculesClass I moleculesType I IFNImmunostimulatory signalsCheckpoint inhibitorsCell surfaceTreatment discontinuationClinical responsePreclinical modelsMalignant cellsSolid tumorsTumor typesColorectal carcinomaGenetic alterationsHMGB1 releasePreclinical Models of Solid Cancers for Testing Cancer Immunotherapies
Exposito F, Connolly K, Tang T, Chiorazzi M, Hunt B, Cardenas J, Nguyen D, Joshi N, Politi K. Preclinical Models of Solid Cancers for Testing Cancer Immunotherapies. Annual Review Of Cancer Biology 2025, 9: 285-305. DOI: 10.1146/annurev-cancerbio-062822-024810.Peer-Reviewed Original ResearchResponse to immunotherapyDevelopment of immunotherapyStandard treatment optionCancer immunotherapy drugsCancer-immune interactionsNumerous cancer typesImmunotherapy resistanceImmunotherapy drugsCancer immunologyPreclinical modelsTreatment optionsMouse modelImmunotherapyCancer typesAdvanced in vitro systemsHuman modelTherapyCancerMiceImmunologyDrugContemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment
Alhajahjeh A, Stahl M, Kim T, Kewan T, Stempel J, Zeidan A, Bewersdorf J. Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment. Expert Review Of Anticancer Therapy 2025, 25: 435-456. PMID: 40122075, DOI: 10.1080/14737140.2025.2483855.Peer-Reviewed Original ResearchMyeloid-derived suppressor cellsAcute myeloid leukemiaMyelodysplastic syndromeSuppressor cellsTumor microenvironmentMyeloid leukemiaEffects of myeloid-derived suppressor cellsTargets myeloid-derived suppressor cellsLeukemic stem cell survivalRisk of leukemia relapseMDSC-targeted therapiesMDSC-mediated immunosuppressionBone marrow nicheStem cell survivalCytokine-mediated pathwaysLeukemia relapseMyeloid diseasesImprove patient outcomesMarrow nichePost-transplantationPreclinical modelsImmunosuppressive propertiesImmunosuppressive componentsFunctional reprogrammingImmune evasionRecommendations for Design, Execution, and Reporting of Studies on Experimental Thoracic Aortopathy in Preclinical Models
Daugherty A, Milewicz D, Dichek D, Ghaghada K, Humphrey J, LeMaire S, Li Y, Mallat Z, Saeys Y, Sawada H, Shen Y, Suzuki T, Zhou Z, Dissections F. Recommendations for Design, Execution, and Reporting of Studies on Experimental Thoracic Aortopathy in Preclinical Models. Arteriosclerosis Thrombosis And Vascular Biology 2025, 45: 609-631. PMID: 40079138, PMCID: PMC12018150, DOI: 10.1161/atvbaha.124.320259.Peer-Reviewed Original ResearchProceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation
Morris Z, Demaria S, Monjazeb A, Formenti S, Weichselbaum R, Welsh J, Enderling H, Schoenfeld J, Brody J, McGee H, Mondini M, Kent M, Young K, Galluzzi L, Karam S, Theelen W, Chang J, Huynh M, Daib A, Pitroda S, Chung C, Serre R, Grassberger C, Deng J, Sodji Q, Nguyen A, Patel R, Krebs S, Kalbasi A, Kerr C, Vanpouille-Box C, Vick L, Aguilera T, Ong I, Herrera F, Menon H, Smart D, Ahmed J, Gartrell R, Roland C, Fekrmandi F, Chakraborty B, Bent E, Berg T, Hutson A, Khleif S, Sikora A, Fong L. Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation. The Lancet Oncology 2025, 26: e152-e170. PMID: 40049206, DOI: 10.1016/s1470-2045(24)00656-9.Peer-Reviewed Original ResearchConceptsAnti-tumor immune responseDelivery of radiotherapyTumor immune recognitionSelection of immunotherapyBiomarker-guided approachesNational Cancer Institute workshopClinical trial dataImmunotherapy combinationsClinical responseImprove patient outcomesPreclinical modelsPatient selectionRadiotherapyImmunotherapyClinical endpointsClinical dataClinical studiesImmune recognitionImmune responseImmune effectsAnimal studiesClinical translationPatient outcomesTrial dataNegative trialsExploring Calcium Channels as Potential Therapeutic Targets in Blast Traumatic Brain Injury
Wachtler N, O’Brien R, Ehrlich B, McGuone D. Exploring Calcium Channels as Potential Therapeutic Targets in Blast Traumatic Brain Injury. Pharmaceuticals 2025, 18: 223. PMID: 40006037, PMCID: PMC11859800, DOI: 10.3390/ph18020223.Peer-Reviewed Original ResearchCalcium signalingCalcium channelsTherapeutic strategiesCalcium homeostasisFunction of calcium channelsDysregulated calcium signalingModulation of injuryTraumatic brain injuryBrain injuryLoss of calcium homeostasisBlast-related traumatic brain injuryDevelopment of neuroprotective interventionsIntracellular calcium dynamicsPlasma membrane stabilityExtracellular calciumBlast traumatic brain injuryPreclinical modelsTherapeutic outcomesNeuroprotective interventionsMembrane abnormalitiesPharmacological inhibitorsNeuronal somataExclusion criteriaCalcium dynamicsSecondary injuryGenetic deficiency or pharmacological inhibition of cGAS–STING signalling suppresses kidney inflammation and fibrosis
Jiao B, An C, Du H, Tran M, Yang D, Zhao Y, Wang P, Hu Z, Zhou D, Wang Y. Genetic deficiency or pharmacological inhibition of cGAS–STING signalling suppresses kidney inflammation and fibrosis. British Journal Of Pharmacology 2025, 182: 1741-1762. PMID: 39833988, DOI: 10.1111/bph.17412.Peer-Reviewed Original ResearchChronic kidney diseaseMacrophage proinflammatory activationDevelopment of renal fibrosisObstructive injuryCGAS-STING signalingProinflammatory activityCGAS-STINGRenal inflammationRenal fibrosisPharmacological inhibitionMyofibroblast formationDamaged tubular epithelial cellsCyclic GMP-AMP synthase (cGAS)-stimulatorBone marrow-derived macrophagesAttenuated kidney fibrosisMarrow-derived macrophagesCGAS-STING signaling pathwayTubular epithelial cellsSignaling in vitroCell-derived DNAPreclinical modelsTubular atrophySTING deficiencyInhibition of cGASKidney inflammationN-acetylcysteine modulates markers of oxidation, inflammation and infection in tuberculosis
Mapamba D, Sabi I, Lalashowi J, Sauli E, Buza J, Olomi W, Mtafya B, Kibona M, Bakuli A, Rachow A, Velen K, Hoelscher M, Ntinginya N, Charalambous S, Churchyard G, Wallis R, consortium T. N-acetylcysteine modulates markers of oxidation, inflammation and infection in tuberculosis. Journal Of Infection 2025, 90: 106379. PMID: 39756697, DOI: 10.1016/j.jinf.2024.106379.Peer-Reviewed Original ResearchAdjunctive N-acetylcysteineN-acetylcysteinePulmonary tuberculosisEx vivo whole blood cultureAffecting IL-10Effect of N-acetylcysteineFar-advanced pulmonary tuberculosisRecovery of lung functionN-acetylcysteine treatmentWhole blood culturesHost-directed therapiesPost-tuberculosis lung diseaseReduction of oxidative stressClearance of MtbAnti-inflammatory effectsBiomarkers of oxidationBlood culturesSecondary endpointsTotal glutathionePreclinical modelsClinical outcomesMtb burdenMonth 1Healthy volunteersIL-10
2024
Neuroinflammatory history results in overlapping transcriptional signatures with heroin exposure in the nucleus accumbens and alters responsiveness to heroin in male rats
Floris G, Zanda M, Dabrowski K, Daws S. Neuroinflammatory history results in overlapping transcriptional signatures with heroin exposure in the nucleus accumbens and alters responsiveness to heroin in male rats. Translational Psychiatry 2024, 14: 500. PMID: 39702361, PMCID: PMC11659471, DOI: 10.1038/s41398-024-03203-4.Peer-Reviewed Original ResearchConceptsResponse to heroinNucleus accumbensHeroin exposureOpioid use disorderSelf-administrationHeroin self-administrationMesolimbic dopamine systemOpioid-induced behaviorsMolecular neuroadaptationsDopamine systemOpioid rewardHeroin intakeBehavioral effectsUse disorderPsychiatric researchLipopolysaccharide (LPS)-induced neuroinflammationPreclinical modelsBehavioral ramificationsSensitivity to opioidsOpioid heroinHeroinMale ratsAccumbensHeightened immune responseNeuroinflammationDecoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma
Schoenfeld D, Djureinovic D, Su D, Zhang L, Lu B, Kamga L, Mann J, Huck J, Hurwitz M, Braun D, Jilaveanu L, Ring A, Kluger H. Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma. JCI Insight 2024, 10: e184545. PMID: 39561007, PMCID: PMC11721305, DOI: 10.1172/jci.insight.184545.Peer-Reviewed Original ResearchAnti-CTLA-4Renal cell carcinomaIL-18IL-18BPCell carcinomaTumor microenvironmentTumor typesPatients treated with immune checkpoint inhibitorsRegulatory T cell levelsAnti-PD-1 treatmentCD8+ T cellsAnti-PD-1Immune checkpoint inhibitorsCell renal cell carcinomaNon-responder patientsMyeloid cell populationsT cell levelsCytokine interleukin-18Anti-cancer efficacySecreted binding proteinCheckpoint inhibitorsResponding patientsPreclinical modelsT cellsMurine modelNew horizons in nuclear cardiology: Imaging of peripheral arterial disease
Callegari S, Mena-Hurtado C, Smolderen K, Thorn S, Sinusas A. New horizons in nuclear cardiology: Imaging of peripheral arterial disease. Journal Of Nuclear Cardiology 2024, 46: 102079. PMID: 39549830, DOI: 10.1016/j.nuclcard.2024.102079.Peer-Reviewed Original ResearchPeripheral arterial diseaseDiagnostic modalitiesRisk stratificationArtery diseaseEarly diagnosisImprove risk stratificationAssociated with higher ratesLower extremity peripheral arterial diseaseEvaluation of therapyClinically relevant areasPreclinical modelsObstructive atherosclerotic diseaseClinical studiesArtery stenosisMicrovascular diseasePreprocedural assessmentPeripheral vasculaturePET imagingAtherosclerotic diseaseNuclear cardiologyTherapeutic interventionsClinical diseaseDiseaseComplex physiologyPerfusionThe Teplizumab Saga: The Challenge of Not Getting Lost in Clinical Translation.
Chatenoud L, Herold K, Bach J, Bluestone J. The Teplizumab Saga: The Challenge of Not Getting Lost in Clinical Translation. Cold Spring Harbor Perspectives In Medicine 2024, a041600. PMID: 39284671, DOI: 10.1101/cshperspect.a041600.Peer-Reviewed Original ResearchMetFinder: A Tool for Automated Quantitation of Metastatic Burden in Histological Sections From Preclinical Models
Karz A, Coudray N, Bayraktar E, Galbraith K, Jour G, Shadaloey A, Eskow N, Rubanov A, Navarro M, Moubarak R, Baptiste G, Levinson G, Mezzano V, Alu M, Loomis C, Lima D, Rubens A, Jilaveanu L, Tsirigos A, Hernando E. MetFinder: A Tool for Automated Quantitation of Metastatic Burden in Histological Sections From Preclinical Models. Pigment Cell & Melanoma Research 2024, 38: e13195. PMID: 39254030, PMCID: PMC11948878, DOI: 10.1111/pcmr.13195.Peer-Reviewed Original ResearchTumor contentMetastasis burdenMetastatic burdenTumor burdenMelanoma metastasesPreclinical modelsMurine modelPreclinical studiesMeasurable metastasesMelanoma researchTherapeutic approachesDeep neural networksHistopathological sectionsMechanisms of melanoma metastasisMetastasisHistological sectionsAI-based algorithmsAutomated quantificationWhole slide imagesAutomated quantitationNeural networkToll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis.
Trujillo G, Regueiro-Ren A, Liu C, Hu B, Sun Y, Ahangari F, Fiorini V, Ishikawa G, Al Jumaily K, Khoury J, McGovern J, Lee C, Peng X, Pivarnik T, Sun H, Walia A, Woo S, Yu S, Antin-Ozerkis D, Sauler M, Kaminski N, Herzog E, Ryu C. Toll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2024, 211: 91-102. PMID: 39189851, PMCID: PMC11755360, DOI: 10.1164/rccm.202401-0065oc.Peer-Reviewed Original ResearchToll-like receptor 9Model of pulmonary fibrosisIdiopathic pulmonary fibrosisPulmonary fibrosisFibroproliferative responseLung diseaseIdiopathic pulmonary fibrosis cohortsExpression of toll-like receptor 9Toll-like receptor 9 activationTransplant-free survivalExpression of MCP-1Cohort of patientsSlow clinical progressionFibrotic lung diseaseAccelerated disease courseFatal lung diseaseIP-10Pharmacodynamic endpointsPreclinical modelsDisease courseClinical progressionPlasma mtDNAMCP-1Receptor 9Mouse modelRenalase peptides reduce pancreatitis severity in mice
Kolodecik T, Guo X, Shugrue C, Guo X, Desir G, Wen L, Gorelick F. Renalase peptides reduce pancreatitis severity in mice. AJP Gastrointestinal And Liver Physiology 2024, 327: g466-g480. PMID: 39010833, PMCID: PMC11427088, DOI: 10.1152/ajpgi.00143.2024.Peer-Reviewed Original ResearchAcute pancreatitisRecombinant renalaseProsurvival propertiesSeverity of acute pancreatitisModel of acute pancreatitisAcute inflammatory injuryClinically relevant modelAnti-inflammatoryHistological tissue injuryPost-ERCPCerulein modelCerulein-inducedInitial dosePancreatitis severityPreclinical modelsImmunohistochemical markersQuantify inflammationInflammatory changesMale micePancreatitisMacrophage populationsTissue injuryCerulein pancreatitisTherapeutic effectRenalaseA multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease
Galasko D, Farlow M, Lucey B, Honig L, Elbert D, Bateman R, Momper J, Thomas R, Rissman R, Pa J, Aslanyan V, Balasubramanian A, West T, Maccecchini M, Feldman H. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease. Alzheimer's Research & Therapy 2024, 16: 151. PMID: 38970127, PMCID: PMC11225352, DOI: 10.1186/s13195-024-01490-z.Peer-Reviewed Original ResearchConceptsOrally administered small moleculeFractional synthesis rateAscending dose studyDose-dependent loweringIRB-approved protocolEarly ADMini-Mental State ExamDose-dependent effectAlzheimer's diseaseBlood patchDouble-blindWell-toleratedCatheter placementPreclinical modelsLumbar punctureDose studyIntravenous infusionMild cognitive impairmentEvaluate safetyPlacebo participantsCognitive measuresStable isotope labeling kineticsActive drugClinical trialsADAS-Cog12Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial
Mukohara T, Park Y, Sommerhalder D, Yonemori K, Hamilton E, Kim S, Kim J, Iwata H, Yamashita T, Layman R, Mita M, Clay T, Chae Y, Oakman C, Yan F, Kim G, Im S, Lindeman G, Rugo H, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso P. Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial. Nature Medicine 2024, 30: 2242-2250. PMID: 38824244, PMCID: PMC11333285, DOI: 10.1038/s41591-024-03060-0.Peer-Reviewed Original ResearchConceptsProgression-free survivalAntitumor activityEpidermal growth factor receptor-negativeBreast cancer preclinical modelsMedian progression-free survivalPhase 1 dose-escalationTreatment-related adverse eventsDose-expansion studyEstrogen receptor-positiveMetastatic breast cancerPhase 1 trialFirst-in-humanFulvestrant combinationReceptor-negativeReceptor-positiveEvaluation of antitumor activitySecondary endpointsPreclinical modelsSafety profileAdverse eventsBreast cancerApproximately doseClinical proofMonotherapyResponse rateEvolution of biotechnological advances and regenerative therapies for endometrial disorders: a systematic review
Rodríguez-Eguren A, Bueno-Fernandez C, Gómez-Álvarez M, Francés-Herrero E, Pellicer A, Bellver J, Seli E, Cervelló I. Evolution of biotechnological advances and regenerative therapies for endometrial disorders: a systematic review. Human Reproduction Update 2024, 30: 584-613. PMID: 38796750, PMCID: PMC11369227, DOI: 10.1093/humupd/dmae013.Peer-Reviewed Original ResearchPlatelet-rich plasmaAsherman's syndromeEndometrial atrophyIntrauterine adhesionsThin endometriumRegenerative therapyMesenchymal stem cellsEndometrial pathologyStem cellsPreclinical modelsEndometrial disordersClinical studiesRisk of poor pregnancy outcomesGrowth factorTreated with surgeryStem cell-based treatmentsPoor pregnancy outcomesTissue repairMaintenance of pregnancyPersonalized treatment regimensImprove reproductive outcomesCell-based treatmentsSystematic reviewHuman bone marrowEndometrial proliferation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply